Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract CancersPRNewsWire • 06/02/23
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023PRNewsWire • 05/31/23
Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare ConferencePRNewsWire • 05/30/23
Compared to Estimates, Jazz (JAZZ) Q1 Earnings: A Look at Key MetricsZacks Investment Research • 05/11/23
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial GuidancePRNewsWire • 05/10/23
Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare ConferencePRNewsWire • 05/02/23
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023PRNewsWire • 04/27/23
Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023PRNewsWire • 04/26/23
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/26/23
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual MeetingPRNewsWire • 04/19/23
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart HealthPRNewsWire • 03/30/23
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical PipelinePRNewsWire • 03/15/23